800 Yeh 2000 30 MA Placebo Geriatric 69 12 5 800 cachexia Randomized control trials versus other interventions Batterham 2001 31 MA 3 arm trial: 1 HIV 15 12 2 400 Mulligan 2007 32 MA MA plus 3 HIV 79 12 5 800 Mwamburi 2004 33 MA plus dietary Oxandrolone HIV 39 8 3 advice 800 Rochon 2003 34 Placebo plus 4 HIV 12 5 3 plus 4 400 Summerbell 1992 35 MA Cyproheptadine HIV 14 12 1 40 plus 5 Timpone 1997 36 MA 4 arm trial: 6 HIV 50 12 2 750 Wanke 2007 37 MA concentrated Oral solution HIV 63 12 3 solution (800mg OD) 575 v 800 Yeh 2010 38 MA MA plus7 ESRF 9 24 5 800 Non randomized trials Golebiewska 2012 39 MA ESRF 32 Up to 6 160 months (analysis at 8 weeks) Graham 1994 40 MA AIDS 14 3 800 Lien 1996 41 MA ESRF 16 8 40 Mwamburi 2004a 42 MA plus8 HIV 29 7 months 800 Rammohan 2005 43 MA ESRF 16 16 400 Von Roenn 1990 44 MA HIV 22 Up to 72 320 plus 9 weeks Table 3: Summary of Included Studies Key 1 a) Dietary counselling b) Nandrolone decanoate (100mg/ fortnight intramuscular injection) c) Megestrol acetate (400mg/day oral) 2 a) 100mg OD, b) 400mg OD c) 800mg OD d) placebo 3 MA plus testosterone versus MA plus placebo 4 nutritional support, amino acid supplementation and protein drinks 5 increased by 40mg alternate weeks to max dose of 160mg if no weight gain 6 a) Dronabinol 2.5mg BD, b) MA 750mg OD, c) MA 750 OD plus Dronabinol 2.5mg BD d) MA 250mg OD plus Dronabinol 2.5mg OD 7 physical training v placebo plus physical training 8 dietary advice plus Oxandrolone 9 increased by 140mg if no weight gain after 12 weeks MA: megestrol acetate, ESRF: end stage renal failure, HIV: human immunodeficiency virus, AIDS: acquired immunodeficiency syndrome, COPD: chronic obstructive pulmonary disease Characteristics of Included Studies and Risk of Bias Assessment See supplementary material.
800 Yeh 2000 30 MA 800 Placebo Geriatric cachexia 69 12 5 Randomized control trials versus other interventions Batterham 2001 31 MA 400 3 arm trial: 1 HIV 15 12 2 Mulligan 2007 32 MA 800 MA plus 3 HIV 79 12 5 Mwamburi 2004 33 MA plus dietary advice 800 Oxandrolone HIV 39 8 3 Rochon 2003 34 plus 4 400 Placebo plus 4 HIV 12 5 3 Summerbell 1992 35 MA 40 plus 5 Cyproheptadine HIV 14 12 1 Timpone 1997 36 MA 750 4 arm trial: 6 HIV 50 12 2 Wanke 2007 37 MA concentrated solution 575 v 800 Oral solution (800mg OD) HIV 63 12 3 Yeh 2010 38 MA 800 MA plus7 ESRF 9 24 5 Non randomized trials Golebiewska 2012 39 MA 160 ESRF 32 Up to 6 months (analysis at 8 weeks) Graham 1994 40 MA 800 AIDS 14 3 Lien 1996 41 MA 40 ESRF 16 8 Mwamburi 2004a 42 MA plus8 800 HIV 29 7 months Rammohan 2005 43 MA 400 ESRF 16 16 Von Roenn 1990 44 MA 320 plus 9 HIV 22 Up to 72 weeks Key Table 3: Summary of Included Studies 1 a) Dietary counselling b) Nandrolone decanoate (100mg/ fortnight intramuscular injection) c) Megestrol acetate (400mg/day oral) 2 a) 100mg OD, b) 400mg OD c) 800mg OD d) placebo 3 MA plus testosterone versus MA plus placebo 4 nutritional support, amino acid supplementation and protein drinks 5 increased by 40mg alternate weeks to max dose of 160mg if no weight gain 6 a) Dronabinol 2.5mg BD, b) MA 750mg OD, c) MA 750 OD plus Dronabinol 2.5mg BD d) MA 250mg OD plus Dronabinol 2.5mg OD 7 physical training v placebo plus physical training 8 dietary advice plus Oxandrolone 9 increased by 140mg if no weight gain after 12 weeks MA: megestrol acetate, ESRF: end stage renal failure, HIV: human immunodeficiency virus, AIDS: acquired immunodeficiency syndrome, COPD: chronic obstructive pulmonary disease Characteristics of Included Studies and Risk of Bias Assessment See supplementary material.